Belong.Life Announces Two Studies Based on Real-World Patient Data at ASCO 2023
Belong.Life has announced that the American Society of Clinical Oncology has published two abstracts in its 2023 Annual Meeting Abstract Book based on data aggregated from the Belong Beating Cancer Together app.
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
Personalis, Inc. has announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.
OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment
OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.
Efficient Transduction of CAR Into T Cells
AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.
Personalis, National Cancer Center Hospital East and Ono Collaborate To Better Predict Immunotherapy Response for Rectal Cancer
Personalis, Inc., National Cancer Center and Ono Pharmaceutical Co., Ltd. have announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.
Personalis, ABRCC and Criterium Announce Major Prospective Clinical Trial
Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.